• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Lau Michael

    4/8/26 8:00:34 PM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $NNNN alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    LAU MICHAEL

    (Last)(First)(Middle)
    FRIEDRICH-EBERT-ANLAGE 35-37

    (Street)
    FRANKFURT AM MAIN60327

    (City)(State)(Zip)

    GERMANY

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    Anbio Biotechnology [ NNNN ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director10% Owner
    XOfficer (give title below)Other (specify below)
    CEO
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Michael Lau04/08/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $NNNN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NNNN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NNNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Song Suki

    3 - Anbio Biotechnology (0001982708) (Issuer)

    4/8/26 8:02:04 PM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Hartzler Nancy

    3 - Anbio Biotechnology (0001982708) (Issuer)

    4/8/26 8:01:39 PM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Lau Michael

    3 - Anbio Biotechnology (0001982708) (Issuer)

    4/8/26 8:00:34 PM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NNNN
    SEC Filings

    View All

    Amendment: SEC Form 20-F/A filed by Anbio Biotechnology

    20-F/A - Anbio Biotechnology (0001982708) (Filer)

    4/9/26 6:04:15 AM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 20-F filed by Anbio Biotechnology

    20-F - Anbio Biotechnology (0001982708) (Filer)

    4/7/26 4:15:24 PM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 6-K filed by Anbio Biotechnology

    6-K - Anbio Biotechnology (0001982708) (Filer)

    2/17/26 4:30:46 PM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $NNNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Anbio Biotechnology to Participate in KeyBanc Capital Markets Healthcare Forum

    FRANKFURT AM MAIN, Germany, March 17, 2026 (GLOBE NEWSWIRE) -- Anbio Biotechnology (NASDAQ:NNNN) ("Anbio" or the "Company"), a global diagnostic company in in-vitro diagnostic (IVD) technologies, announced today that its CEO will participate in the upcoming KeyBanc Capital Markets Virtual Healthcare Forum on Wednesday, March 18, 2026. Anbio's CEO is scheduled to participate in a fireside chat and will have the opportunity to share the Company's previously disclosed business updates, strategic initiatives, and product development with the investor community. Anbio's participation in the conference reflects the Company's continued engagement with the investment community and supports its c

    3/17/26 4:30:00 PM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

    FRANKFURT, Germany, Aug. 08, 2025 (GLOBE NEWSWIRE) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care. As cases continue to rise across tropical and subtropical regions, timely detection and differentiation from other arboviral infections like Dengue and Zika remain critical. The test, based on immunochromatographic technology, enables reliable qualitative detection of Chikungunya-specific antibodies in human serum, plasma, or whole blood. This addition strengthens Anbio's infectious disease diag

    8/8/25 9:05:14 PM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions

    BRUSSELS, May 15, 2025 (GLOBE NEWSWIRE) -- Anbio Biotechnology, a global leader in in-vitro diagnostic (IVD) technologies, is pleased to announce its participation in three major international exhibitions this May: EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and the 47th ACMTT 2025 in Bangkok. These events reflect Anbio's strategic commitment to expanding its global footprint across human and animal healthcare, building new partnerships, and sharing its vision for accessible, high-performance diagnostics. As healthcare systems around the world seek faster, more accurate, and decentralized testing solutions, Anbio is well-positioned to meet this demand through a diversified

    5/15/25 1:05:47 AM ET
    $NNNN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care